NASDAQ · Financial Statements

Akebia Therapeutics, Inc. (AKBA) Financial Statements

$0.57 NASDAQ: AKBA Market Cap $157.09M

Akebia Therapeutics, Inc. most recently reported annual revenue of $236.0M, a net loss of $5.0M. Revenue declined at an average annual rate of 4.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Akebia Therapeutics, Inc.: Revenue rose from $2.0M in 2016 to $236.0M in 2025, a change of +11700.0% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -8889.9% to 9.9%, a shift of +8899.9 percentage points; the most recent year shows a net loss of $5.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$2.0M$178.0M$208.0M$335.0M$295.0M$212.0M$292.0M$195.0M$160.0M$236.0M
Operating Expenses$138.0M$258.0M$386.0M$621.0M$672.0M$476.0M$373.0M$241.0M$211.0M$213.0M
Operating Profit$-136.0M$-80.0M$-178.0M$-286.0M$-378.0M$-265.0M$-81.0M$-46.0M$-50.0M$23.0M
Operating Margin-8889.9%-44.9%-85.8%-85.5%-128.2%-125.0%-27.6%-23.8%-31.5%9.9%
Other Income$1.0M$3.0M$6.0M$0$-7.0M$-18.0M$-13.0M$-6.0M$-19.0M$-27.0M
Interest$0$0$0$1.0M$9.0M$20.0M$16.0M$6.0M$18.0M$24.0M
Depreciation$0$1.0M$2.0M$36.0M$35.0M$38.0M$38.0M$38.0M$38.0M$1.0M
Profit Before Tax$-136.0M$-77.0M$-172.0M$-286.0M$-385.0M$-282.0M$-94.0M$-52.0M$-69.0M$-4.0M
Tax$660,000$3.6M$16.5M$2.3M$0$0$0$0$0$-43.6M
Net Profit$-136.0M$-77.0M$-172.0M$-280.0M$-385.0M$-282.0M$-94.0M$-52.0M$-69.0M$-5.0M
EPS$-3.60$-1.77$-1.47$-2.36$-2.53$-1.48$-0.58$-0.28$-0.33$-0.02
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$42.0M$56.0M$33.0M$44.0M$37.0M$46.0M$57.0M$62.0M$59.0M$58.0M$54.0M$49.0M
Operating Expenses$55.0M$55.0M$48.0M$52.0M$50.0M$61.0M$44.0M$48.0M$54.0M$66.0M$58.0M$55.0M
Operating Profit$-13.0M$1.0M$-15.0M$-9.0M$-13.0M$-14.0M$14.0M$14.0M$4.0M$-9.0M$-5.0M$-6.0M
Operating Margin-31.0%2.5%-45.8%-20.0%-33.4%-30.8%23.6%22.6%7.6%-14.8%-8.8%-12.9%
Interest$1.0M$1.0M$2.0M$2.0M$7.0M$7.0M$8.0M$7.0M$5.0M$5.0M$5.0M$3.0M
Profit Before Tax$-14.0M$1.0M$-18.0M$-9.0M$-20.0M$-23.0M$6.0M$0$1.0M$-11.0M$-9.0M$-9.0M
Tax$0$0$0$0$0$0$0$0$53.3M$-9.0M$-1.4M$-790,000
Net Profit$-14.0M$1.0M$-18.0M$-9.0M$-20.0M$-23.0M$6.0M$0$1.0M$-12.0M$-9.0M$-9.0M
EPS$-0.08$0.00$-0.09$-0.04$-0.10$-0.10$0.03$0.00$0.00$-0.05$-0.03$-0.03

Over the 10 years reported for Akebia Therapeutics, Inc., cash stood at $185.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.13 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$300.0M$364.0M$997.0M$771.0M$644.0M$529.0M$356.0M$242.0M$221.0M$377.0M
Current Assets$296.0M$358.0M$468.0M$310.0M$371.0M$271.0M$185.0M$118.0M$114.0M$185.0M
Cash$187.0M$70.0M$105.0M$148.0M$229.0M$150.0M$90.0M$43.0M$52.0M$185.0M
Inventory$0$0$114.0M$116.0M$61.0M$37.0M$22.0M$16.0M$16.0M$16.0M
Receivables$34.0M$34.0M$17.0M$39.0M$29.0M$52.0M$40.0M$39.0M$34.0M$47.0M
Fixed Assets$3.0M$4.0M$8.0M$39.0M$35.0M$41.0M$34.0M$16.0M$10.0M$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$73.0M$249.0M$219.0M$2.0M$42.0M$0$0$0$0$0
Other Assets$0$0$55.0M$55.0M$55.0M$59.0M$59.0M$59.0M$59.0M$59.0M
Total Liabilities$232.0M$245.0M$361.0M$376.0M$397.0M$455.0M$351.0M$272.0M$270.0M$344.0M
Current Liabilities$114.0M$144.0M$266.0M$208.0M$187.0M$261.0M$130.0M$100.0M$81.0M$163.0M
Borrowings$0$0$15.0M$108.0M$126.0M$189.0M$100.0M$104.0M$189.0M$216.0M
Other Liabilities$232.0M$245.0M$346.0M$268.0M$270.0M$266.0M$251.0M$168.0M$81.0M$128.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$68.0M$119.0M$636.0M$395.0M$248.0M$74.0M$5.0M$-31.0M$-49.0M$33.0M

For Akebia Therapeutics, Inc., operating cash flow was positive in 2 of 10 reported years; free cash flow in the latest year was $68.0M; free cash flow was positive in 2 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$58.0M$-56.0M$-97.0M$-257.0M$-110.0M$-253.0M$-73.0M$-23.0M$-41.0M$68.0M
Investing Cash Flow$10.0M$-179.0M$67.0M$205.0M$-40.0M$40.0M$0$0$0$-8.0M
Financing Cash Flow$0$1.0M$1.0M$0$1.0M$45.0M$40.0M$0$-1.0M$0
Net Cash Flow$138.0M$-117.0M$36.0M$43.0M$81.0M$-79.0M$-59.0M$-49.0M$9.0M$133.0M
Free Cash Flow$55.0M$-58.0M$-99.0M$-264.0M$-111.0M$-253.0M$-73.0M$-23.0M$-41.0M$68.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-7.24
FCF Yield17.34%
Quick Ratio1.35
Interest Coverage-1.90
Return 1Y-69.58%
Return 3Y0.00%
Return 5Y-55.48%

Akebia Therapeutics, Inc. (AKBA) financials — frequently asked questions

What is Akebia Therapeutics, Inc.'s annual revenue?

Akebia Therapeutics, Inc. (AKBA) reported annual revenue of $236.0M in its most recent fiscal year.

What is Akebia Therapeutics, Inc.'s net profit?

Akebia Therapeutics, Inc. (AKBA) reported a net loss of $5.0M in its most recent fiscal year.

What is AKBA EV/EBITDA?

Akebia Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -7.24. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
AKBA Overview AKBA Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.